Mentor’s Prevelle Silk
This article was originally published in The Gray Sheet
Executive SummaryHyaluronic acid-based dermal filler containing the local anesthetic lidocaine for pain reduction gains FDA market go-ahead for treatment of moderate to severe facial lines, folds and wrinkles. The first in a new line of HA dermal fillers that Mentor is developing with Genzyme under an October 2006 R&D pact, Prevelle Silk will roll out "shortly" on a targeted basis to experienced dermatology and plastic surgery customers, Mentor says. A broader U.S. launch of the product is anticipated by Mentor "later this year," in conjunction with a second lidocaine-containing dermal filler which is under FDA review (1"The Gray Sheet" Nov. 6, 2006, p. 14)
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.